Provided by Tiger Trade Technology Pte. Ltd.

Perspective Therapeutics

2.76
+0.04001.47%
Post-market: 2.790.0300+1.09%19:30 EDT
Volume:2.62M
Turnover:7.23M
Market Cap:314.64M
PE:-2.08
High:2.82
Open:2.77
Low:2.69
Close:2.72
52wk High:6.16
52wk Low:1.96
Shares:114.00M
Float Shares:70.82M
Volume Ratio:1.63
T/O Rate:3.70%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.3300
EPS(LYR):-1.3971
ROE:-39.57%
ROA:-22.28%
PB:0.97
PE(LYR):-1.98

Loading ...

Analysts Offer Insights on Healthcare Companies: Perspective Therapeutics (CATX) and Integra Lifesciences (IART)

TIPRANKS
·
Yesterday

Perspective Therapeutics [212Pb]VMT01 Melanoma Trial Data Set for SITC 2026 Presentation

Reuters
·
Oct 02

Regions, Netflix, Targa, Dynatrace, CATX trending with analysts

TIPRANKS
·
Sep 19

William Blair Initiates Perspective Therapeutics With Outperform Rating

MT Newswires Live
·
Sep 18

Perspective Therapeutics initiated with an Outperform at William Blair

TIPRANKS
·
Sep 18

U.S. Research Roundup-Amrize, Carmax, VF Corp

Reuters
·
Sep 18

Perspective Therapeutics: Merck Collaboration and 2H26 Catalysts Reinforce Buy Rating and Unchanged $11 Price Target

TIPRANKS
·
Sep 15

Perspective Therapeutics Price Target Maintained with a $11.00/Share by Wedbush

Dow Jones
·
Sep 15

Perspective Therapeutics Enters Cancer Clinical Trial Collaboration With Merck; Shares Up Pre-Bell

MT Newswires Live
·
Sep 14

Perspective Therapeutics Partners with Merck to Test [212Pb]PSV359 with Keytruda in FAP-Α-Positive Solid Tumors

Reuters
·
Sep 14

Perspective Therapeutics, - Co Sponsors Study; Merck Provides Pembrolizumab at no Cost

THOMSON REUTERS
·
Sep 14

Perspective Therapeutics Announces Clinical Collaboration and Supply Agreement with Merck to Evaluate [212PB]Psv359 in Combination with Keytruda® (Pembrolizumab) in Fap-Α Positive Solid Tumors

THOMSON REUTERS
·
Sep 14

Perspective Therapeutics [212Pb]VMT-Α-NET Cohort Safety, Efficacy Data Set for ENA Symposium Poster Session

Reuters
·
Sep 11

Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the 38th EORTC-NCI-AACR Symposium 2026

GlobeNewswire
·
Sep 11

Perspective Therapeutics Updates Radiopharmaceutical Oncology Pipeline Outlook

TIPRANKS
·
Sep 09

Lantheus Alpha Therapy Disposes of USD 773,930 in Perspective Therapeutics Common Shares

Reuters
·
Sep 09

Lantheus Alpha Therapy Disposes of USD 358,084 Perspective Therapeutics Common Shares

Reuters
·
Sep 05

Lantheus Holdings Reports Sale of 78,145 Perspective Therapeutics Shares Worth $245,641

Reuters
·
Sep 03

BMO Capital Initiates Perspective Therapeutics at Outperform

MT Newswires Live
·
Aug 19

Perspective Therapeutics is Maintained at Neutral by B of a Securities

Dow Jones
·
Aug 15